Seattle Genetics Inc (SGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 110

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Seattle Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 14
Venture Financing 15
Unum Therapeutics Raises USD65 Million in Series B Financing 15
Partnerships 17
Seattle Genetics Enters into Clinical Agreements for SGN-LIV1A 17
Genmab Exercises Option for Licensing Agreement with Seattle Genetics 18
Seattle Genetics Enters into Agreement with Genentech 19
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 20
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 21
Genmab Enters into Research Agreement with Seattle Genetics 22
Seattle Genetics Expands Co-Development Agreement With AbbVie 23
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 25
Seattle Genetics Enters Into Co-Development Agreement With Oxford BioTherapeutics 26
Seattle Genetics Exercises Its Option Co-Development Agreement With Agensys 27
Genmab Enters Into Research Collaboration With Seattle Genetics 28
Seattle Genetics Enters Into Collaboration With Abbott 29
Licensing Agreements 30
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 30
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 31
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 32
Bayer HealthCare Enters Into Licensing Agreement With Seattle Genetics 33
Seattle Genetics Extends Licensing Agreement With Millennium 34
Seattle Genetics Enters Into Licensing Agreement With Pfizer 35
Equity Offering 36
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 36
Unum Therapeutics Plans to Raise USD5 Million in Private Placement of Shares 38
Seattle Genetics Completes Private Placement Of Shares For US$9 Million 39
Seattle Genetics Announces Exercise Of Underwriters Over-Allotment Option For US$178 Million 40
Acquisition 42
Seattle Genetics Acquires 2.8% Stake in Immunomedics 42
Seattle Genetics Inc - Key Competitors 44
Seattle Genetics Inc - Key Employees 45
Seattle Genetics Inc - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
Oct 26, 2017: Seattle Genetics Reports Third Quarter 2017 Financial Results 47
Jul 27, 2017: Seattle Genetics Reports Second Quarter 2017 Financial Results 49
Apr 27, 2017: Seattle Genetics Reports First Quarter 2017 Financial Results 51
Feb 09, 2017: Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results 53
Oct 27, 2016: Seattle Genetics Reports Third Quarter 2016 Financial Results 55
Jul 26, 2016: Seattle Genetics Reports Second Quarter 2016 Financial Results 57
Apr 28, 2016: Seattle Genetics Reports First Quarter 2016 Financial Results 59
Feb 09, 2016: Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results 61
Corporate Communications 63
Oct 04, 2016: Seattle Genetics Announces Executive Promotions and Leadership Appointment 63
Product News 64
12/05/2016: Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting 64
11/10/2016: Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS (Brentuximab Vedotin) in Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma 66
11/03/2016: Seattle Genetics Announce data on Denintuzumab Mafodotin at ASH 2016 68
10/20/2016: Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at ISHL 2016 69
10/18/2016: Takeda Showcases Continued Commitment in Hodgkin Lymphoma During 10th International Symposium on Hodgkin Lymphoma 71
05/27/2016: Takeda Receives Positive CHMP Opinion for ADCETRIS (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma 72
Mar 30, 2017: Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting 73
01/21/2017: Johnson & Weaver Announces Filing of Class Action Complaint Against Seattle Genetics Encourages all Investors to Contact the Firm for Information 75
Product Approvals 76
Jul 06, 2016: Takeda Receives European Commission Approval of ADCETRIS (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma 76
Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma 77
Clinical Trials 78
Dec 07, 2017: Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium 78
Mar 06, 2017: FDA Lifts Clinical Hold on Seattle Genetics' Phase 1 Trials of Vadastuximab Talirine 80
Dec 27, 2016: Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A) 81
Dec 10, 2016: Seattle Genetics Highlights Phase 1 Data for Novel Antibody-Drug Conjugate SGN-LIV1A in Patients with Metastatic Breast Cancer at San Antonio Breast Cancer Symposium 82
Dec 05, 2016: Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting 83
Dec 05, 2016: Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting 85
Dec 03, 2016: Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting 87
Dec 03, 2016: Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma 89
Nov 08, 2016: Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma 92
Nov 03, 2016: Seattle Genetics Announces ASH 2016 Abstracts Highlighting Data on ADCETRIS (brentuximab vedotin) Development Programs 94
Nov 03, 2016: Seattle Genetics Announces ASH 2016 Abstracts Highlighting Data on vadastuximab talirine (SGN-CD33A) Development Programs 96
Nov 03, 2016: Takeda to Present Clinical Data on ADCETRIS (brentuximab vedotin) During 58th American Society of Hematology Annual Meeting 98
Aug 01, 2016: Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma 99
Jul 18, 2016: Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood 101
Jul 18, 2016: Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood 103
Jun 11, 2016: Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association 105
Apr 18, 2016: Seattle Genetics Highlights Data on SGN-LIV1A at the American Association for Cancer Research Annual Meeting 107
Apr 18, 2016: Seattle Genetics Highlights Data on 2-fluorofucose (2FF) at the American Association for Cancer Research Annual Meeting 108
Apr 18, 2016: Seattle Genetics Highlights Data on ADCETRIS at the American Association for Cancer Research Annual Meeting 109
Appendix 110
Methodology 110
About GlobalData 110
Contact Us 110
Disclaimer 110

List of Tables
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Seattle Genetics Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Seattle Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 14
Unum Therapeutics Raises USD65 Million in Series B Financing 15
Seattle Genetics Enters into Clinical Agreements for SGN-LIV1A 17
Genmab Exercises Option for Licensing Agreement with Seattle Genetics 18
Seattle Genetics Enters into Agreement with Genentech 19
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 20
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 21
Genmab Enters into Research Agreement with Seattle Genetics 22
Seattle Genetics Expands Co-Development Agreement With AbbVie 23
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 25
Seattle Genetics Enters Into Co-Development Agreement With Oxford BioTherapeutics 26
Seattle Genetics Exercises Its Option Co-Development Agreement With Agensys 27
Genmab Enters Into Research Collaboration With Seattle Genetics 28
Seattle Genetics Enters Into Collaboration With Abbott 29
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 30
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 31
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 32
Bayer HealthCare Enters Into Licensing Agreement With Seattle Genetics 33
Seattle Genetics Extends Licensing Agreement With Millennium 34
Seattle Genetics Enters Into Licensing Agreement With Pfizer 35
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 36
Unum Therapeutics Plans to Raise USD5 Million in Private Placement of Shares 38
Seattle Genetics Completes Private Placement Of Shares For US$9 Million 39
Seattle Genetics Announces Exercise Of Underwriters Over-Allotment Option For US$178 Million 40
Seattle Genetics Acquires 2.8% Stake in Immunomedics 42
Seattle Genetics Inc, Key Competitors 44
Seattle Genetics Inc, Key Employees 45
Seattle Genetics Inc, Subsidiaries 46

List of Figures
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Seattle Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 11

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Seattle Genetics Inc (SGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027